NovaPoint Capital LLC Cuts Stock Position in Zoetis Inc. (NYSE:ZTS)

NovaPoint Capital LLC cut its position in Zoetis Inc. (NYSE:ZTS) by 3.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,977 shares of the company’s stock after selling 155 shares during the quarter. NovaPoint Capital LLC’s holdings in Zoetis were worth $648,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Darwin Wealth Management LLC bought a new stake in shares of Zoetis during the 3rd quarter valued at $31,000. First Personal Financial Services bought a new stake in shares of Zoetis during the 3rd quarter valued at $33,000. Capital Performance Advisors LLP bought a new position in Zoetis in the 3rd quarter worth about $33,000. Dunhill Financial LLC increased its stake in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the last quarter. Finally, Fortitude Family Office LLC increased its stake in Zoetis by 1,387.5% in the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after acquiring an additional 222 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Up 2.0 %

Shares of ZTS stock opened at $175.65 on Thursday. The stock has a market capitalization of $79.25 billion, a PE ratio of 33.02, a P/E/G ratio of 2.72 and a beta of 0.90. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53. The business has a 50-day moving average of $169.41 and a 200 day moving average of $179.35. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter last year, the business posted $1.36 EPS. The business’s revenue was up 11.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be issued a $0.50 dividend. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 annualized dividend and a yield of 1.14%. This is a boost from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ZTS shares. UBS Group started coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. Leerink Partners started coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. JPMorgan Chase & Co. upped their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, Morgan Stanley cut their price objective on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zoetis presently has an average rating of “Buy” and a consensus target price of $215.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.